| Indication | obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity |
| Drug | semaglutide |
| Mechanism of Action | GLP-1 receptor agonist |
| Company | Novo Nordisk A/S |
| Trial Phase | Phase 3 |
| Trial Acronym | OASIS |
| Category | Regulatory Milestone |
| Sub Category | Approval Granted |
| Therapeutic Area | Endocrinology & Metabolic Diseases |
| Regulatory Body | European Commission (EC), European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) |
| Approval Date | July 15, 2026 |
| Approved Market/Region | European Union (EU) member states |
| Dosage (Pill) | once-daily oral semaglutide 25 mg |
| Dosage (Injection) | Wegovy® 7.2 mg injection |
| Comparator | placebo |
| Patient Population Size (OASIS 4) | 307 adults |
| Weight Loss (Pill) | approximately 17% (vs 3% with placebo) |
| Weight Loss (Injection) | 21% |
| Follow-up Duration (OASIS 4) | 64 weeks |
European Commission Approves Novo Nordisk's Wegovy Pill for Weight Management
Novo Nordisk announced that the European Commission (EC) has granted marketing authorization for Wegovy® pill (once-daily oral semaglutide 25 mg) for adults with obesity or overweight with at least one weight-related comorbidity in the EU, as an adjunct to a reduced-calorie diet and increased physical activity. This marks the first oral GLP-1 receptor agonist for weight management in the EU, demonstrating approximately 17% weight loss in the OASIS 4 trial. The EC also approved Wegovy® 7.2 mg injection in a single-dose pen, which showed 21% weight loss.
- The EC approval of Wegovy® pill is a landmark moment, making it the first GLP-1 receptor agonist available in tablet form for weight management across all EU member states. This is the fifth regulatory approval for Wegovy® pill, following its availability in the US, UK, UAE, and Bahrain, underscoring its growing global presence and offering a new, simpler treatment option for many patients.
- The approval is supported by the extensive OASIS clinical trial program, specifically OASIS 4. In this 64-week Phase 3b trial, once-daily oral semaglutide 25 mg demonstrated clinically meaningful and statistically significant weight loss of approximately 17% compared to 3% with placebo, when used alongside lifestyle intervention. Around one in three participants achieved 20% weight loss or more.
- The safety and tolerability profile of oral semaglutide is consistent with the established injectable semaglutide, with adverse-event-related discontinuations nearly comparable to placebo (6.9% vs 5.9%). Additionally, the European Commission also granted approval for Wegovy® 7.2 mg injection in a single-dose pen, providing another effective treatment option for people living with obesity.
The Unmet Needs Driving Oral Semaglutide's Significance
Despite significant progress in obesity management, current therapeutic strategies face considerable limitations, highlighting a persistent unmet need. These challenges span lifestyle interventions, pharmacotherapy, and surgical procedures, often resulting in suboptimal long-term outcomes for patients with obesity or overweight and associated comorbidities.
Limited Efficacy of Lifestyle Interventions: Lifestyle modifications centered on diet and exercise are foundational to weight management but frequently prove insufficient for achieving and sustaining clinically significant weight loss. As standalone therapies, they rarely produce durable results, and studies have shown that even specialized dietary recommendations may fail to meaningfully alter patient habits or biometrics like BMI and waist circumference over the long term.
Challenges in Pharmacotherapy: Historically, anti-obesity medications offered modest efficacy, with average weight loss of 5–10% that fell short of patient and clinician expectations. While newer incretin-based therapies like GLP-1 receptor agonists demonstrate superior weight loss, their use is hampered by common gastrointestinal adverse events (e.g., nausea, vomiting, diarrhea), which impair quality of life, compromise treatment adherence, and are a major driver of discontinuation in real-world settings.
Barriers and Risks of Bariatric Surgery: Although highly effective for weight loss, bariatric surgery is not a suitable or desirable option for all patients. The procedure is associated with significant upfront costs, higher procedural risks, and the potential for long-term complications, including nutritional deficiencies that require lifelong management. Furthermore, the long-term efficacy of certain procedures, such as laparoscopic adjustable gastric banding (LAGB), has been questioned compared to other surgical techniques.
Suboptimal Management of Comorbidities: In clinical practice, patients with obesity and related comorbidities often fail to achieve recommended treatment targets. For instance, obese patients, particularly those with type 2 diabetes, are significantly less likely to reach their LDL-cholesterol goals even when prescribed statins. This gap is often due to a combination of factors, including insufficient medication dosing and the overall complexity of managing multiple conditions, underscoring the need for a more effective, integrated, and multidisciplinary approach.
Frequently Asked Questions
References
- [1] Snijder MB, van Dam RM et al.. A prospective study of dairy consumption in relation to changes in metabolic risk factors: the Hoorn Study. Obesity (Silver Spring, Md.). 2008 Mar. 18239556
- [2] Jung SH, Ha KH et al.. Visceral Fat Mass Has Stronger Associations with Diabetes and Prediabetes than Other Anthropometric Obesity Indicators among Korean Adults. Yonsei medical journal. 2016 May. 26996568
- [3] Kloock S, Ziegler CG et al.. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?. Pharmacology & therapeutics. 2023 Nov. 37879540
- [4] Ziolkowski SL, Long J et al.. Chronic Kidney Disease and the Adiposity Paradox: Valid or Confounded?. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2019 Nov. 30709713
- [5] Dash S. Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy. Diabetes, obesity & metabolism. 2024 Sep. 39157881
- [6] Azam M, Sakinah LF et al.. Prevalence and determinants of obesity among individuals with diabetes in Indonesia. F1000Research. 2022. 37928804
- [7] Yancy WS Jr, Olsen MK et al.. Relationship between obesity and health-related quality of life in men. Obesity research. 2002 Oct. 12376587
- [8] Moholdt T, Hayman M et al.. The Role of Lifestyle Intervention in the Prevention and Treatment of Gestational Diabetes. Seminars in reproductive medicine. 2020 Nov. 33472245
- [9] Leong KS, Wilding JP. Obesity and diabetes. Bailliere's best practice & research. Clinical endocrinology & metabolism. 1999 Jul. 10761864
- [10] Gardener SL, Rainey-Smith SR et al.. Diet and Inflammation in Alzheimer's Disease and Related Chronic Diseases: A Review. Journal of Alzheimer's disease : JAD. 2016. 26682690
- [11] Siqueira KS, Appolinario JC et al.. Overweight, obesity, and binge eating in a non-clinical sample of five Brazilian cities. Obesity research. 2004 Dec. 15687391
- [12] Frost PA, Chen S et al.. Research methodology for in vivo measurements of resting energy expenditure, daily body temperature, metabolic heat and non-viral tissue-specific gene therapy in baboons. Research in veterinary science. 2020 Dec. 32979746
- [13] Luesma MJ, Fernando J et al.. Surgical Treatment of Obesity. Special Mention to Roux-en-Y Gastric Bypass and Vertical Gastrectomy. Frontiers in endocrinology. 2022. 35432187
- [14] Chapman AE, Kiroff G et al.. Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review. Surgery. 2004 Mar. 14976485
- [15] Castellanos-Gutiérrez A, Sánchez-Pimienta TG et al.. Higher dietary magnesium intake is associated with lower body mass index, waist circumference and serum glucose in Mexican adults. Nutrition journal. 2018 Dec 5. 30518394
- [16] Hatemi H, Yumuk VD et al.. Prevalence of overweight and obesity in Turkey. Metabolic syndrome and related disorders. 2003 Dec. 18370653
- [17] Arhire LI, Niță O et al.. Validation of the Dutch Eating Behavior Questionnaire in a Romanian Adult Population. Nutrients. 2021 Oct 29. 34836141
- [18] Bernardelli LV, Kortt MA et al.. The association between BMI and self-reported health among a Brazilian sample: a cross-sectional study. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2024 Apr. 38217772
- [19] Patil P, Lalwani P et al.. A multidimensional functional fitness score has a stronger association with type 2 diabetes than obesity parameters in cross sectional data. PloS one. 2021. 33544739
- [20] Muhundan M, Dash S. Bariatric Surgery in the Era of GLP1RA: A Narrative Review. Advances in therapy. 2026 Mar. 41627368
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
